Literature DB >> 17592774

Estrogen receptors outside the nucleus in breast cancer.

Ellis R Levin1, Richard J Pietras.   

Abstract

The estrogen receptor (ER) is the single most powerful predictor of breast cancer prognosis as well as an important contributor to the biology of carcinogenesis. In addition, endocrine therapy targeting ER directly (SERMS) or indirectly (aromatase inhibitors) forms the mainstay of adjuant therapy. Traditionally, human tumors are scored for the amount and presence of ER. However, this has centered on the population of ER found in the transformed epithelial cell nucleus. Over the last 40 years, it has been appreciated that additional cellular ER pools exist, in cytoplasm and at the plasma membrane. In this review, we discuss the important functions of extra-nuclear ER in breast cancer, including integration of function with nuclear ER.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592774     DOI: 10.1007/s10549-007-9618-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  67 in total

1.  Effects of cadmium on estrogen receptor mediated signaling and estrogen induced DNA synthesis in T47D human breast cancer cells.

Authors:  Yu Zang; Shelly Odwin-Dacosta; James D Yager
Journal:  Toxicol Lett       Date:  2008-11-11       Impact factor: 4.372

2.  ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.

Authors:  Semir Vranic; Zoran Gatalica; Hao Deng; Snjezana Frkovic-Grazio; Lisa M J Lee; Olga Gurjeva; Zhao-Yi Wang
Journal:  J Clin Pathol       Date:  2010-11-02       Impact factor: 3.411

Review 3.  Androgens and esophageal cancer: What do we know?

Authors:  Olga A Sukocheva; Bin Li; Steven L Due; Damian J Hussey; David I Watson
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

4.  Does a nonclassical signaling mechanism underlie an increase of estradiol-mediated gonadotropin-releasing hormone receptor binding in ovine pituitary cells?

Authors:  Tracy L Davis; Jennifer D Whitesell; Jeremy D Cantlon; Colin M Clay; Terry M Nett
Journal:  Biol Reprod       Date:  2011-07-06       Impact factor: 4.285

5.  Point mutations in the ERα Gαi binding domain segregate nonnuclear from nuclear receptor function.

Authors:  Qian Wu; Ken Chambliss; Wan-Ru Lee; Ivan S Yuhanna; Chieko Mineo; Philip W Shaul
Journal:  Mol Endocrinol       Date:  2012-12-14

Review 6.  From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?

Authors:  Victoria Shang Wu; Noriko Kanaya; Chiao Lo; Joanne Mortimer; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-05-18       Impact factor: 4.292

7.  Heat shock protein 27 is required for sex steroid receptor trafficking to and functioning at the plasma membrane.

Authors:  Mahnaz Razandi; Ali Pedram; Ellis R Levin
Journal:  Mol Cell Biol       Date:  2010-05-03       Impact factor: 4.272

Review 8.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

9.  ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.

Authors:  Sheng-Li Lin; Li-Ying Yan; Xin-Tian Zhang; Ju Yuan; Mo Li; Jie Qiao; Zhao-Yi Wang; Qing-Yuan Sun
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

10.  Estrogen-like effects of cadmium in vivo do not appear to be mediated via the classical estrogen receptor transcriptional pathway.

Authors:  Imran Ali; Pauliina E Penttinen-Damdimopoulou; Sari I Mäkelä; Marika Berglund; Ulla Stenius; Agneta Akesson; Helen Håkansson; Krister Halldin
Journal:  Environ Health Perspect       Date:  2010-06-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.